Automate Your Wheel Strategy on INCR
With Tiblio's Option Bot, you can configure your own wheel strategy including INCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INCR
- Rev/Share 4.0074
- Book/Share 9.0557
- PB 0.5342
- Debt/Equity 0.5325
- CurrentRatio 1.7279
- ROIC -0.1414
- MktCap 263262702.5355
- FreeCF/Share 0.0
- PFCF 0.0
- PE -3.0955
- Debt/Assets 0.2772
- DivYield 0
- ROE -0.1639
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel
Read More
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel
Read More
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Acquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies
Read More
About InterCure Ltd. (INCR)
- IPO Date 2019-01-28
- Website https://www.intercure.co
- Industry Drug Manufacturers - Specialty & Generic
- CEO Alexander Rabinovich
- Employees 320